These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 19719336)

  • 1. Aprepitant: a review of its use in the prevention of nausea and vomiting.
    Curran MP; Robinson DM
    Drugs; 2009; 69(13):1853-78. PubMed ID: 19719336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting.
    Dando TM; Perry CM
    Drugs; 2004; 64(7):777-94. PubMed ID: 15025555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
    Warr DG; Hesketh PJ; Gralla RJ; Muss HB; Herrstedt J; Eisenberg PD; Raftopoulos H; Grunberg SM; Gabriel M; Rodgers A; Bohidar N; Klinger G; Hustad CM; Horgan KJ; Skobieranda F
    J Clin Oncol; 2005 Apr; 23(12):2822-30. PubMed ID: 15837996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.
    Massaro AM; Lenz KL
    Ann Pharmacother; 2005 Jan; 39(1):77-85. PubMed ID: 15562136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium.
    Annemans L; Strens D; Lox E; Petit C; Malonne H
    Support Care Cancer; 2008 Aug; 16(8):905-15. PubMed ID: 17965891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.
    Kim JE; Jang JS; Kim JW; Sung YL; Cho CH; Lee MA; Kim DJ; Ahn MJ; Lee KY; Sym SJ; Lim MC; Jung H; Cho EK; Min KW
    Support Care Cancer; 2017 Mar; 25(3):801-809. PubMed ID: 27826874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.
    Rapoport BL; Jordan K; Boice JA; Taylor A; Brown C; Hardwick JS; Carides A; Webb T; Schmoll HJ
    Support Care Cancer; 2010 Apr; 18(4):423-31. PubMed ID: 19568773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
    Celio L; Agustoni F; Testa I; Dotti K; de Braud F
    Tumori; 2012; 98(3):279-86. PubMed ID: 22825501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy.
    Pendergrass K; Hargreaves R; Petty KJ; Carides AD; Evans JK; Horgan KJ
    Drugs Today (Barc); 2004 Oct; 40(10):853-63. PubMed ID: 15605119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic and preventive antiemetic effect of aprepitant in Japanese patients with thoracic malignancies who truly need it.
    Ito S; Tsukiyama I; Ando M; Katakami M; Hamanaka R; Kosaka K; Matsubara A; Nishimura M; Tanaka H; Asai N; Yokoe N; Takahashi A; Baba K; Matsuura K; Yamaguchi E; Kubo A
    Support Care Cancer; 2015 Apr; 23(4):905-12. PubMed ID: 25223352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann CH; Herrstedt J
    Expert Opin Drug Saf; 2011 May; 10(3):449-62. PubMed ID: 21417835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
    Hesketh PJ; Warr DG; Street JC; Carides AD
    Support Care Cancer; 2011 Sep; 19(9):1297-302. PubMed ID: 20623144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong.
    Chan SL; Jen J; Burke T; Pellissier J
    Asia Pac J Clin Oncol; 2014 Mar; 10(1):80-91. PubMed ID: 24571059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fosaprepitant Dimeglumine: A Review in the Prevention of Nausea and Vomiting Associated with Chemotherapy.
    Garnock-Jones KP
    Drugs; 2016 Sep; 76(14):1365-72. PubMed ID: 27510503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
    Grunberg SM; Dugan M; Muss H; Wood M; Burdette-Radoux S; Weisberg T; Siebel M
    Support Care Cancer; 2009 May; 17(5):589-94. PubMed ID: 19037667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aprepitant (EMEND): the role of substance P in nausea and vomiting.
    Prommer E
    J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
    Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
    BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.
    Moore S; Tumeh J; Wojtanowski S; Flowers C
    Value Health; 2007; 10(1):23-31. PubMed ID: 17261113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.